Back/Pace Life Sciences Boosts Efficiency with Labguru Digital Integration in Laboratories
pharma·March 20, 2026·avxl

Pace Life Sciences Boosts Efficiency with Labguru Digital Integration in Laboratories

ED
Editorial
Cashu Markets·3 min read
TL;DR
  • Anavex Life Sciences is highlighted in the context of broader digital transformation trends in the Life Sciences sector.
  • Pace® Life Sciences enhances laboratory efficiency by implementing Labguru’s digital workflows, improving documentation and compliance.
  • The collaboration with Labguru assures Pace® Life Sciences maintains high-quality service while scaling operations in the market.

### Advancing Laboratory Efficiency: The Impact of Digital Integration at Pace® Life Sciences

Pace® Life Sciences, a leading contract development and manufacturing organization (CDMO), recently adopts Cenevo's Labguru platform to enhance its laboratory documentation processes. The Labguru platform offers a comprehensive, cloud-based laboratory data management system that incorporates features such as electronic lab notebooks (ELNs) and laboratory information management systems (LIMS). This strategic implementation allows Pace® to centralize operations, streamline workflows, and improve overall compliance within their analytical laboratories. Cynthia Hansen, IT Program Director at Pace®, underscores the platform’s scalability, signifying that it grows alongside the company’s evolving needs while bolstering client service through effective collaboration with the Labguru team.

The transition to Labguru’s digital workflows delivers several operational advantages. Key improvements include a significant reduction in manual data entry, which enhances the accuracy and integrity of laboratory data. Enhanced inventory visibility allows scientists at Pace® to prioritize critical tasks, steering away from cumbersome paper-based processes. Adam Michel, Senior ELN Specialist, emphasizes Labguru’s adaptability, highlighting its customizable features that align with Pace®’s unique operational framework. By fostering an environment of efficiency, this integration assures that Pace® Life Sciences remains well-positioned to meet regulatory standards while maintaining high-quality service across the pharmaceutical and biopharmaceutical sectors.

As the deployment of Labguru unfolds across four GMP analytical services laboratories, Pace® Life Sciences plans further expansion in alignment with its growth strategy. Gal Hasse, VP Product Labguru at Cenevo, expresses pride in the partnership, underscoring the role of advanced, AI-enabled platforms in scaling laboratory and manufacturing services. The collaboration not only enhances operational execution but also aligns with the overarching goal of ensuring quality and compliance in an increasingly competitive market.

In a parallel initiative within the Life Sciences sector, Agilisium announces a robust $5.5 million investment aimed at revolutionizing AI technology deployment in pharmaceutical and biotech companies. Its innovative model, dubbed “Forward Deployment Experts” (FDX), seeks to bridge the gap between AI capabilities and practical applications by embedding experts directly within client organizations. This approach aims to dismantle the barriers that hinder AI integration, such as insufficient combined expertise in technology and regulatory frameworks.

This strategic shift positions Agilisium as a frontrunner in the Life Sciences landscape. The initiative reflects the sector's evolving landscape as companies pivot toward AI-enhanced operations, reinforcing the importance of skilled talent in driving AI applications that deliver real-world results. As both Pace® Life Sciences and Agilisium initiate comprehensive digital transformations, they contribute to a larger trend steering the Life Sciences industry toward enhanced operational efficiency and innovation.

Cashu Markets
Cashu
Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Markets
Cashu
Markets

Setting up your session...